Universe Pharmaceuticals INC (UPC)

Revenue by Segment

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018
Traditional Chinese Medicine Derivatives (TCMD) Products	17.86M	23.02M	32.31M	40.14M	47.98M
Traditional Chinese Medicine Derivatives (TCMD) Products Growth	-22.44%	-28.74%	-19.52%	-16.34%	56.27%
Total	17.86M	23.02M	32.31M	40.14M	47.98M
Total Growth	-22.44%	-28.74%	-19.52%	-16.34%	56.27%

Revenue by Geography

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018
China	17.86M	23.02M	32.31M	40.14M	47.98M
China Growth	-22.44%	-28.74%	-19.52%	-16.34%	56.27%
Total	17.86M	23.02M	32.31M	40.14M	47.98M
Total Growth	-22.44%	-28.74%	-19.52%	-16.34%	56.27%

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 19, 2026

Data Sources Report a data error